Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab PK and Tolerability at Different Flow Rates
NCT02085473Phase 1Completed
- Sponsor
- MedImmune
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of tralokinumab in asthma (4 cohorts), sponsored by MedImmune. Primary endpoints: Area Under the Concentration-Time Curve From Zero to Infinity at Day 57, Maximum Observed Serum Concentration at Day 57 and 5 more. Started Mar 2014; status: completed.
02
Drugs
tralokinumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02085473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085473.